High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 6, 2015, Pages 1261-1266

  Kawamura, Takahisa ^a   Hata, Akito ^b   Takeshita, Jumpei ^b   Fujita, Shiro ^b   Hayashi, Michio ^a   Tomii, Keisuke ^a   Katakami, Nobuyuki ^b  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

EGFR TKI; High dose erlotinib; Leptomeningeal metastases; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; BILIRUBIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LEPTOMENINGEAL METASTASIS; LIVER DYSFUNCTION; MALE; MIDDLE AGED; NAUSEA; NEUROLOGIC DISEASE; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMATOUS MENINGITIS; CHEMICALLY INDUCED; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84929944008     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2759-y     Document Type: Article

References (29)

1. Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344-2348
2. Heon S, Yeap BY, Britt GJ et al (2010) Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16:5873-5882
3. Langer CJ, Mehta MP (2005) Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207-6219
4. Sundstr€om JT, Minn H, Lertola KK et al (1998) Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 30:296-299
5. Jamal-Hanjani M, Spicer J (2012) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18:938-944
6. Morris PG, Reiner AS, Szenberg OR et al (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7:382-385
7. Chamberlain MC, Kormanik PA, Barba D et al (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694-699
8. Gwak HS, Joo J, Kim S et al (2013) Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 8:599-605
9. Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80-84
10. Lee E, Keam B, Kim DW et al (2013) Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 8:1069-1074
11. Katayama T, Shimizu J, Suda K et al (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415-1419
12. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
13. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792
14. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043
15. Sequist LV, Waltman BA, Dias-Santagata et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26
16. Grommes C, Oxnard GR, Kris MG et al (2011) "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13:1364-1369
17. Jackman DM, Holmes AJ, Lindeman N et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517-4520
18. Dhruva N, Socinski MA (2009) Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 27:e31-e32
19. Clarke JL, Pao W, Wu N et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283-286
20. Kuiper JL, Smit EF (2013) High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-one with a remarkable thoracic response as well. Lung Cancer 80:102-105
21. Hata A, Kaji R, Fujita S et al (2011) High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol 6:653-654
22. Togashi Y, Masago K, Masuda S et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70:399-405
23. Nagai Y, Huqun MH et al (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276-7282
24. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103-119
25. Milton DT, Azzoli CG, Heelan RT et al (2006) A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:1034-1041
26. Asahina H, Oizumi S, Inoue A et al (2010) Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 79:423-429
27. Heon S, Nishino M, Goldberg SB et al (2012) Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. J Clin Oncol 30 (suppl; abstr 7525)
28. Welsh JW, Komaki R, Amini A et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895-902
29. Herbst RS, Ansari R, Bustin F et al (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846-1854